C-12蛋白芯片检测12种肿瘤标记物的血清学表达情况

目的探讨C-12蛋白芯片系统定量检测12种肿瘤标记物在常见的11种恶性肿瘤患者血清学的表达情况,并进行临床应用研究,为恶性肿瘤的诊治提供依据。方法用C-12定量检测临床初诊为肿瘤的宋手术的患者382例、健康人组445例、普查组1685例、术后组62例的12种肿瘤标记物。初诊肿瘤患者全部经病理证实。结果经病理证实确诊为恶性肿瘤组的12种肿瘤标记物血清学表达情况较其他3组差异有极其显著性(P<0.01),C-12联合检测的灵敏度85.1%,特异性90.3%,阳性预测值96.5%,阴性预测值68.4%,有效性88.7%。同阳性率最高的CA125、CEA比较差异有显著性(P<0.01)。结论C-12蛋白芯片联合检测12种肿瘤标记物提高了恶性肿瘤诊断的阳性率,为正常普查人群和处于亚临床阶段的患者恶性肿瘤病尽早检出和鉴别提供可靠的检测方法。动态观察12种肿瘤标记物的血清学表达情况,为恶性肿瘤患者的预后、转归、治疗提供可靠依据。

The serum expression condition of 12 tumor markers by protein chip systerm c-12 detection

Objective To study the serum expression condition of 12 tumor markers in 11 kinds of cancer padents by protein chip systerm(c-12),and make clinical using study to provide evidence for the clinical diagnosis of the cancer.Methods Use the systern c-12 to determine quantitatively the 12 tumor markers.All patients of first diagnosis were evidenced with padlology.Results The differences of the serum concentration of 12 tumor markers were statistically significant between patients with cancer that were evidenced with padlology and other three groups(p<0.01).By the systerm c-12,the positive rate of the allied was 85.1%,the specificity was 90.3%,positive anticipate was 96.5%,negtive anticipate was 68.4%,and accaracy was 88.7%.The differences with CA125,CEA of the highest positive rate and control groups were statically significant(p<0.01).Conclution The allied detetion of 12 tumor markers with systerm c-12 has raised positive diagnosis rate of the cancer patients and provided the credible detection methods for the high risk groups and those patients who have sub-clinical symptoms.Continuously watch the serum expression condition of 12 tumor markers has provided the credible methods for the condition of cancer patients.